Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine Manufacturer...

Hard To Treat Diseases (HTDS.PK) Agreement With 2nd Largest Vaccine
Manufacturer in China Yunnan Walvax Biotech Co

SHENZHEN, China, July 13 /PRNewswire-FirstCall/ - Hard to Treat Diseases
(HTDS.PK) www.htdsmedical.com - subsidiary, Mellow Hope signed an agreement
with Yunnan Walvax Biotech Co., Ltd for the Haemophilus influenza type b
conjugate vaccine. Yunnan Walvax Biotech Co. Ltd is the second biggest
manufacturer of Haemophilus influenza type b conjugate vaccine in China. This
agreement / arrangement now sets the stage for Mellow Hope to be fully
authorized to conduct the international marketing of Haemophilus influenza
type b conjugate vaccine in the global market.
In other corporate news, the company plans on commencing the registration in
Chile, Indonesia, Egypt, and Russia within this month with the brand name
"MEVAC-Hib".
The company will provide further details as they become available.

Safe Harbor Statement

Information in this news release may contain statements about future
expectations, plans, prospects or performance of Hard To Treat Diseases Inc
that constitute forward-looking statements for purposes of the safe harbor
Provision's under the Private Securities Litigation Reform Act of 1995. The
words or phrases "can be," "expects," "may affect," "believed," "estimate,"
"project," and similar words and phrases are intended to identify such
forward-looking statements. Hard To Treat Diseases Inc cautions you that any
forward-looking information provided by or on behalf of Hard To Treat Diseases
Inc is not a guarantee of future performance. None of the information in this
press release constitutes or is intended as an offer to sell securities or
investment advice of any kind. Hard To Treat Diseases Inc's actual results may
differ materially from those anticipated in such forward-looking statements as
a result of various important factors, some of which are beyond Hard To Treat
Diseases Inc's control. In addition to those discussed in Hard To Treat
Diseases Inc's press releases, public filings, and statements by Hard To Treat
Diseases Inc's management, including, but not limited to, Hard To Treat
Diseases Inc's estimate of the sufficiency of its existing capital resources,
Hard To Treat Diseases Inc's ability to raise additional capital to fund
future operations, Hard To Treat Diseases Inc's ability to repay its existing
indebtedness, the uncertainties involved in estimating market opportunities
and, in identifying contracts which match Hard To Treat Diseases Inc's
capability to be awarded contracts. All such forward-looking statements are
current only as of the date on which such statements were made. Hard To Treat
Diseases Inc does not undertake any obligation to publicly update any
forward-looking statement to reflect events or circumstances after the date on
which any such statement is made or to reflect the occurrence of unanticipated
events.

CONTACT: For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any corporate matters, please contact
corporate@htdsmedical.com, www.htdsmedical.com

SOURCE Hard to Treat Diseases

For medical and scientific dialogue inquiry only, please contact
medicalinfo@htdsmedical.com; For any corporate matters, please contact
corporate@htdsmedical.com, www.htdsmedical.com